Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
CYP1A1	1543	HYPERICIN	CHEMBL286494		NCI	14633740
CYP1A1	1543	2-METHOXYESTRADIOL	CHEMBL299613		DrugBank	12810639
CYP1A1	1543	LIOTHYRONINE SODIUM	CHEMBL1201119		NCI	1322573
CYP1A1	1543	CHRYSIN	CHEMBL117	inhibitor	GuideToPharmacologyInteractions
CYP1A1	1543	QUERCETIN	CHEMBL50		NCI	10359656
CYP1A1	1543	PHENOBARBITAL	CHEMBL40		PharmGKB
CYP1A1	1543	CARBAMAZEPINE	CHEMBL108		PharmGKB
CYP1A1	1543	RUTIN	CHEMBL226335		NCI	14633740
CYP1A1	1543	BIOCHANIN	CHEMBL131921		NCI	15479032
CYP1A1	1543	VALPROIC ACID	CHEMBL109		PharmGKB
CYP1A1	1543	RISPERIDONE	CHEMBL85		NCI	10048600
CYP1A1	1543	CHEMBL1255648	CHEMBL1255648		NCI	9890552
CYP1A1	1543	PROMETHAZINE	CHEMBL643		NCI	4024659
CYP1A1	1543	SPIRONOLACTONE	CHEMBL1393		NCI	7079590
CYP1A1	1543	LANSOPRAZOLE	CHEMBL480		NCI	8647108
CYP1A1	1543	DAUNORUBICIN	CHEMBL178		NCI	15588138
CYP1A1	1543	DOXORUBICIN	CHEMBL53463		NCI	15588138

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
CYP1A1	rs2472297	T	caffeine	metabolism/PK	yes	This variant is associated with higher 17X/137X, suggesting they are associated with faster caffeine metabolism.	Allele T is associated with increased metabolism of caffeine as compared to allele C.	27702941	1451198580
CYP1A1	rs1048943	AG + GG	capecitabine	efficacy	yes	Women with genotypes AG + GG have significantly longer progression-free survival than women with the genotype AA.	Genotypes AG + GG are associated with increased response to capecitabine and docetaxel in women with Breast Neoplasms as compared to genotype AA.	22426923	981475614
CYP1A1	rs1048943	C	warfarin	dosage	no	No association was found between this variant and warfarin-maintenance dose. Please note that A/G alleles were given (complementary alleles are given here).	Allele C is not associated with increased dose of warfarin in people with an international normalized ratio (INR) of 2.0-3.0 as compared to allele T.	22248286	827845820
CYP1A1	rs2606345	AC + CC	deferasirox	metabolism/PK	yes	Weight-adjusted trough concentrations (ng/ml/kg). In multivariate analyses, the AA genotype was found to predict drug concentrations below 20,000 ng/ml, which is the trough concentration cutoff value that predicts therapeutic efficacy. The AA genotype was associated with a decreased chance of having drug concentrations above the cutoff for therapeutic efficacy.	Genotypes AC + CC is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotype AA.	25348619	1333193034
CYP1A1	rs3826041	CC	warfarin	dosage	yes	All participants were warfarin-naive.	Genotype CC is associated with increased dose of warfarin in people with heart valve replacement as compared to genotypes AA + AC.	27740732	1448267332
CYP1A1	rs2606345	AA	deferasirox	metabolism/PK	no	The genotype was not associated with area under the concentration curve (AUC) above the effectiveness cutoff of 360 micrograms/mL/h as compared in univariate analysis.	Genotype AA is not associated with concentrations of deferasirox in people with beta-Thalassemia as compared to genotypes AC + CC.	27193993	1448101354
CYP1A1	rs4646903	AA + AG	deferasirox	metabolism/PK	no	The genotypes were not associated with area under the concentration curve (AUC) above the effectiveness cutoff of 360 micrograms/mL/h as compared in univariate analysis.	Genotypes AA + AG are not associated with concentrations of deferasirox in people with beta-Thalassemia as compared to genotype GG.	27193993	1448101346
CYP1A1	rs2606345	AC + CC	deferasirox	metabolism/PK	yes	Half life was also longer in CC/CA compared to AA. Authors state "This suggested a homozygous A allele gain of function, thus lower drug concentrations" even though "located in intronic region of CYP1A1 gene".	Genotypes AC + CC is associated with increased trough concentration of deferasirox in children with beta-Thalassemia as compared to genotype AA.	28346059	1448612764
CYP1A1	rs2606345	AA + AC	exemestane	metabolism/PK	no	No significant difference in exemestane concentrations were seen between the three genotypes.	Genotypes AA + AC are not associated with concentrations of exemestane in women with Breast Neoplasms as compared to genotype CC.	27549341	1448495164
CYP1A1	CYP1A1*1, CYP1A1*2A	*2A	granisetron	metabolism/PK	yes	CYP1a1*2a carriers had a significantly higher granisetron clearance and decreased AUC compared with patients without the allele in pregnant women with nausea and vomiting.	CYP1A1 *2A is associated with increased clearance of granisetron as compared to CYP1A1 *1/*1.	27809336	1448426866
CYP1A1	CYP1A1*1, CYP1A1*2A	*1/*2A + *2A/*2A	exemestane	metabolism/PK	no	No significant difference in exemestane concentrations were seen between the three genotypes.	CYP1A1 *1/*2A + *2A/*2A are not associated with concentrations of exemestane in women with Breast Neoplasms as compared to CYP1A1 *1/*1.	27549341	1448495665
CYP1A1	rs2606345	AA	antiepileptics	efficacy	yes	Bonferroni-corrected significance level was p<0.017. The AA genotype (as well as the A allele) was overrepresented in female poor responders to antiepileptic drugs. Poor responders were those who had one or more seizures during the 10 months of analysis of patients taking antiepileptics (the study period was a year, but the first 2 months were excluded to allow drugs to reach steady-state levels). Note that no significant results were seen when considering males (n=194, p=0.627) or the total population (n=351, p=0.072). The A allele was found to lower CYP1A1 promoter activity by 70-80%.	Genotype AA is associated with decreased response to antiepileptics in women with Epilepsy as compared to genotypes AC + CC.	26951882	1448424049
CYP1A1	rs1048943	C	imatinib	dosage	no	No significant association between genotype and chance of requiring an imatinib dose reduction. Please note that alleles have been complemented to the positive strand.	Allele C is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele T.	30713339	1450933440